基于递归分割分析构建并验证预后模型以指导局部复发鼻咽癌再程放疗
本研究回顾性分析531例局部复发鼻咽癌患者,训练队列271例(2006—2012年),验证队列260例(2013—2016年)。多因素分析筛选出年龄、复发T分期和EBV DNA为独立预后因素,基于rT分期和EBV DNA建立RPA预后模型并划分三个风险组。再程放疗可使低危组(P < 0.001)和中危组(P = 0.017)患者获益,高危组未见生存获益(P = 0.328),结果在验证队列中得到验证。
要点
- 年龄、复发T分期和EBV DNA是局部复发鼻咽癌的独立预后因素。
- 基于rT分期和EBV DNA的RPA模型将患者分为低、中、高危三组。
- 再程放疗可获益于低危(P < 0.001)和中危(P = 0.017)组,高危组无获益(P = 0.328)。
核心结论
- 年龄、复发T分期和EBV DNA被确定为局部复发鼻咽癌的独立预后因素。
- 建立了纳入rT分期和EBV DNA的RPA预后模型,可指导局部复发鼻咽癌的个体化治疗。
研究设计与样本
- 回顾性分析531例局部复发鼻咽癌患者,训练队列271例(2006—2012年),验证队列260例(2013—2016年)。
- 主要终点为总生存,多因素分析筛选显著预后因素(P < 0.05),采用递归分割分析结合优化二元分割算法建立预后模型。
主要发现
- 多因素分析识别出年龄、复发T分期和EBV DNA三个独立预后因素。
- RPA模型结合rT分期和EBV DNA衍生出五个预后组,经组间两两比较后生成三个风险组。
- 再程放疗使低危组获益(P < 0.001),中危组获益(P = 0.017),高危组无生存获益关联(P = 0.328)。
- 风险分层和再程放疗疗效结果在验证队列中得到验证。
临床怎么用
- 作者建立的RPA预后模型可用于指导局部复发鼻咽癌的个体化治疗。
- 低危和中危组患者可从再程放疗中获益,高危组未发现再程放疗与生存获益的关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In this study, we aimed to establish and validate an integrated prognostic model for locally recurrent nasopharyngeal carcinoma (lrNPC) patients, and evaluate the benefit of re-radiotherapy (re-RT) in patients with different risk levels. MATERIALS AND METHODS: In total, 531 patients with lrNPC were retrospectively reviewed in this study, including 271 patients from 2006 to 2012 as the training cohort and 260 patients from 2013 to 2016 as the validation cohort. Overall survival (OS) was the primary endpoint. Multivariate analysis was performed to select the significant prognostic factors (P < 0.05). A prognostic model for OS was derived by recursive partitioning analysis (RPA) combining independent predictors using the algorithm of optimized binary partition. RESULTS: Three independent prognostic factors (age, relapsed T [rT] stage, and Epstein-Barr virus [EBV] DNA) were identified from multivariate analysis. Five prognostic groups were derived from an RPA model that combined rT stage and EBV DNA. After further pair-wise comparisons of survival outcome in each group, three risk groups were generated. We investigated the role of re-RT in different risk groups, and found that re-RT could benefit patients in the low (P < 0.001) and intermediate-risk subgroups (P = 0.017), while no association between re-RT and survival benefit was found in the high-risk subgroup (P = 0.328). The results of risk stratification and re-RT efficacy were verified in the validation cohort. CONCLUSION: Age, rT stage and EBV DNA were identified as independent predictors for lrNPC. We established an integrated RPA-based prognostic model for OS incorporating rT stage and EBV DNA, which could guide individual treatment for lrNPC.
引用
- Sun XS, Zhu MY, Wen DX, et al. Establishment and validation of a recursive partitioning analysis based prognostic model for guiding re-radiotherapy in locally recurrent nasopharyngeal carcinoma patients. Radiother Oncol. 2022. PMID: 35101468. doi:10.1016/j.radonc.2022.01.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。